Patents by Inventor Keun Kuk LEE

Keun Kuk LEE has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Pyridine derivative inhibiting RAF kinase and vascular endothelial growth factor receptor, method for preparing same, pharmaceutical composition containing same, and use thereof
    Patent number: 10844062
    Abstract: The present invention provides a novel pyridine derivative, a pharmaceutically acceptable salt thereof, a method for preparing the same, and a pharmaceutical composition containing the same as an active ingredient. The pyridine derivative according to the present invention inhibits Raf kinase (B-Raf, Raf-1, or B-RafV600E) and a vascular endothelial growth factor receptor (VEGFR2) involved in angiogenesis, and thus, can be favorably used for the prevention or treatment of melanoma, colorectal cancer, prostate cancer, thyroid cancer, lung cancer, pancreatic cancer, ovarian cancer, or the like, which is induced by RAS mutation.
    Type: Grant
    Filed: January 11, 2017
    Date of Patent: November 24, 2020
    Assignees: Incheon University Industry Academic Cooperation Foundation, Samjin Pharmaceutical Co., Ltd., Bamichem Co., Ltd.
    Inventors: Eui Hwan Cho, Hee Jong Shin, Min Hyo Ki, Ho Seok Kwon, Jae Woong Lee, Jeong Ho Joo, Keun Kuk Lee, Jong Min Kim, Yong Bin Park, Sung Hyun Kang, Hyoung Min Cho, Hyun Tae Kim, Soon Kil Ahn, Sung Pyo Hong, Sung Hye Kim
  • Pyridine Derivative Inhibiting RAF Kinase and Vascular Endothelial Growth Factor Receptor, Method for Preparing Same, Pharmaceutical Composition Containing Same, and Use Thereof
    Publication number: 20190300531
    Abstract: The present invention provides a novel pyridine derivative, a pharmaceutically acceptable salt thereof, a method for preparing the same, and a pharmaceutical composition containing the same as an active ingredient. The pyridine derivative according to the present invention inhibits Raf kinase (B-Raf, Raf-1, or B-RafV600E) and a vascular endothelial growth factor receptor (VEGFR2) involved in angiogenesis, and thus, can be favorably used for the prevention or treatment of melanoma, colorectal cancer, prostate cancer, thyroid cancer, lung cancer, pancreatic cancer, ovarian cancer, or the like, which is induced by RAS mutation.
    Type: Application
    Filed: January 11, 2017
    Publication date: October 3, 2019
    Inventors: Eui Hwan CHO, Hee Jong SHIN, Min Hyo KI, Ho Seok KWON, Jae Woong LEE, Jeong Ho JOO, Keun Kuk LEE, Jong Min KIM, Yong Bin PARK, Sung Hyun KANG, Hyoung Min CHO, Hyun Tae KIM, Soon Kil AHN, Sung Pyo HONG, Sung Hye KIM